Findings published in online and print editions of Cancer Research demonstrate potential of miR-29c* to act as an independent prognostic factor for time to progression as well as survival after surgery. Ability to forecast outcomes for malignant pleural mesothelioma (MPM) may enable clinicians to provide aggressive therapy to the most appropriate patients. Read More...

Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program. Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility. Read More...

Michael Harbut, M.D., MPH, co-director of the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) at the Barbara Ann Karmanos Cancer Institute in Detroit, MI, and chief of the Center for Occupational and Environmental Medicine Wayne State University, announced the use of a new technology to aid in the diagnosis of asbestos-related lung disease. Read More...

The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. Read More...